Effect of Clopidogrel on the Steady-State Pharmacokinetics of Fluvastatin
作者： Surya P. Ayalasomayajula , Sujata Vaidyanathan , Charisse Kemp , Pratapa Prasad , Alfred Balch
关键词:
摘要: This study assessed the effects of clopidogrel, a CYP 2C9 inhibitor, on fluvastatin pharmacokinetics in healthy volunteers. The combined clopidogrel-fluvastatin treatment platelet function were also determined. Subjects received 80 mg (extended-release formulation) alone days 1 through 9, and 300 clopidogrel (loading dose) day 10, 75 (maintenance 11 19. Compared to with alone, AUC was similar C max increased marginally (15.7%) concomitant clopidogrel. Platelet aggregation inhibited by 33% two hours after loading dose 47% at steady state, that reported for treatment. authors conclude coadministration has no clinically relevant effect or inhibition
sci-hub.se 参考文章(22)
C. H. MIELKE, M. M. KANESHIRO, I. A. MAHER, J. M. WEINER, S. I. RAPAPORT, The Standardized Normal Ivy Bleeding Time and Its Prolongation by Aspirin Blood. ,vol. 34, pp. 204- 215 ,(1969) , 10.1182/BLOOD.V34.2.204.204
Wei C. Lau, David G.M. Carville, Eric R. Bates, Clinical Significance of the Atorvastatin–Clopidogrel Drug–Drug Interaction Circulation. ,vol. 110, ,(2004) , 10.1161/01.CIR.0000137956.92971.4A
Denise Barilla, Pratapa Prasad, Martine Hubert, Kavita Gumbhir-Shah, Steady-state pharmacokinetics of fluvastatin in healthy subjects following a new extended release fluvastatin tablet, Lescol XL. Biopharmaceutics & Drug Disposition. ,vol. 25, pp. 51- 59 ,(2004) , 10.1002/BDD.378
F. Mach, D. Senouf, P. Fontana, F. Boehlen, G. Reber, Y. Daali, P. de Moerloose, U. Sigwart, Not all statins interfere with clopidogrel during antiplatelet therapy. European Journal of Clinical Investigation. ,vol. 35, pp. 476- 481 ,(2005) , 10.1111/J.1365-2362.2005.01522.X
Christie M. Ballantyne, Franco Pazzucconi, Xavier Pintó, John P. Reckless, Evan Stein, James McKenney, Michele Bortolini, Yann Tong Chiang, Efficacy and tolerability of fluvastatin extended-release delivery system: a pooled analysis. Clinical Therapeutics. ,vol. 23, pp. 177- 192 ,(2001) , 10.1016/S0149-2918(01)80001-1
Wei C. Lau, Lucy A. Waskell, Paul B. Watkins, Charlene J. Neer, Kevin Horowitz, Amy S. Hopp, Alan R. Tait, David G.M. Carville, Kirk E. Guyer, Eric R. Bates, Atorvastatin Reduces the Ability of Clopidogrel to Inhibit Platelet Aggregation A New Drug–Drug Interaction Circulation. ,vol. 107, pp. 32- 37 ,(2003) , 10.1161/01.CIR.0000047060.60595.CC
CG Mc Donnell, G Shorten, FNAM Van Pelt, None, Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia. ,vol. 60, pp. 747- 753 ,(2005) , 10.1111/J.1365-2044.2005.04110.X
Adnan Kastrati, Steffi Harlfinger, Olga Gorchakova, Andreas Lazar, Nicolas von Beckerath, Albert Schömig, Edgar Schömig, Dirk Taubert, Pharmacokinetics of clopidogrel after administration of a high loading dose Thrombosis and Haemostasis. ,vol. 92, pp. 311- 316 ,(2004) , 10.1160/TH04-02-0105
Heather D. Langtry, Anthony Markham, Fluvastatin: a review of its use in lipid disorders. Drugs. ,vol. 57, pp. 583- 606 ,(1999) , 10.2165/00003495-199957040-00009
Tanja Richter, Thomas E. Mürdter, Georg Heinkele, Jürgen Pleiss, Stephan Tatzel, Matthias Schwab, Michel Eichelbaum, Ulrich M. Zanger, Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine Journal of Pharmacology and Experimental Therapeutics. ,vol. 308, pp. 189- 197 ,(2004) , 10.1124/JPET.103.056127